

Applicants: Ron S. Israeli et al.  
Serial No.: 08/470,735  
Filed : June 6, 1995  
Page 2

of the prostate specific membrane antigen having within its structure the consecutive amino acid sequence Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35).--

--115. (New) An antibody which binds to prostate specific membrane antigenic polypeptide comprising a fragment of the prostate specific membrane antigen having within its structure the consecutive amino acid sequence Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36).--

--116. (New) An antibody which binds to prostate specific membrane antigenic polypeptide comprising a fragment of the prostate specific membrane antigen having within its structure the consecutive amino acid sequence Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).--

--117. (New) An antibody which binds to prostate specific membrane antigenic polypeptide comprising a fragment of the prostate specific membrane antigen having within its structure the following uninterrupted amino acid sequences:

- (a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);  
(b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36);  
(c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37); and  
(d) Ala-Gly-Ala-Leu-Val-Leu-Ala-Gly-Gly-Phe-Phe-Leu-Leu-Gly-Phe-Leu-Phe (SEQ ID NO:38).--
- MG17*

--118. (New) An antibody which binds to prostate specific membrane antigenic polypeptide comprising a fragment of the prostate specific membrane antigen having within its structure the following uninterrupted amino acid sequences:

- (a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);  
(b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); and  
(c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).--

Applicants: Ron S. Israeli et al.  
Serial No.: 08/470,735  
Filed : June 6, 1995  
Page 3

- 119. (New) An antibody which binds to prostate specific membrane antigenic polypeptide comprising a fragment of the prostate specific membrane antigen having within its structure the consecutive amino acid sequence set forth in SEQ ID NO:2.--
- 120. (New) An antibody which binds to prostate specific membrane antigenic polypeptide comprising amino acids, the sequence of which corresponds to an outside region of prostate specific membrane antigen.--
- 121. (New) An antibody which binds to prostate specific membrane antigenic polypeptide consisting essentially of amino acids, the sequence of which corresponds to the sequence of the outside region of prostate specific membrane antigen, wherein the polypeptide comprises within its structure the following consecutive amino acids sequences:  
(a) Asp-Glu-Leu-Lys-Ala-Glu (SEQ ID NO: 35);  
(b) Asn-Glu-Asp-Gly-Asn-Glu (SEQ ID NO: 36); and  
(c) Lys-Ser-Pro-Asp-Glu-Gly (SEQ ID NO: 37).--
- 11  
MMG2
- 122. (New) The antibody of any one of claims 114-121, wherein the antibody is a monoclonal antibody.--
- 123. (New) A composition of matter comprising the antibody of any one of claims 114-121 and an agent conjugated to the antibody.--
- 124. (New) The composition of matter of claim 123, wherein the agent is a radioisotope or toxin.--
- 125. (New) A composition comprising a carrier and the composition of matter of claim 123.--

Applicants: Ron S. Israeli et al.  
Serial No.: 08/470,735  
Filed : June 6, 1995  
Page 4

1  
--126. (New) A method of imaging prostate cancer in a subject which comprises administering to the subject the composition of matter of claim 123, wherein the agent is an imaging agent under conditions permitting formation of a complex between the composition of matter and prostate specific membrane antigen, and obtaining an image of any complex so formed.--

Remarks

Claims 94-96, 98-101 and 105-113 were pending in the subject application. Applicants have hereinabove canceled claims 94-96, 98-101 and 105-113 without prejudice to their right to pursue the subject matter of these claims in a later-filed application and added new claims 114-126. Support for these claims may be found inter alia in the specification as follows: claims 114-119: page 32, lines 29-32, page 31, lines 14-17, page 22, lines 10-11, page 30, line 32, Figure 14-1, page 30, lines 9-19, page 32, lines 24-27, page 53, line 20 to page 54, line 1; claim 120: page 31, lines 14-17, page 55, lines 5-16; claim 121: page 32, lines 29-32, page 55, lines 5-16, page 30, line 32, figure 14-1, page 30, lines 9-10, page 32, lines 24-27; claim 122: page 32, lines 16-22; claims 123-126: page 32, line 34 to page 33, line 26. Applicants contend that this amendment does not involve any issue of new matter. Entry of this amendment is respectfully requested such that claims 114-126 will be pending.

status of application

Applicants acknowledge the Examiner's statement that the finality of the previous Office action is withdrawn pursuant to 37 CFR 1.129(a) and that applicant's first submission after final filed on June 17, 1999 has been entered.

Restriction

The Examiner stated that newly submitted claims 107-112 are directed to an invention that is independent or distinct from the